Will Tseng, MD
Critical Care (Intensivists) · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 2
- 2 carriers
- Office
- 1
Offices
1 location · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Hospitals listed: El Camino Health. That is not proof they admit you there this week.
Plans that list them
2 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Tseng’s office at (408) 356-8400 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
2 of 2 plans
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A105896 · Current
Licensed to practise in California · since 2008 · expires 2028-04-30 · Dartmouth Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$214,091
Medicare paid this office $214,091 for 361 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 176 | $52,889 | $164 |
| Return visit (30+ min) | 170 | $30,480 | $111 |
| Critical care, first 30-74 minutes | 40 | $18,074 | $186 |
| New patient visit (60+ min) | 55 | $10,997 | $200 |
| Test to examine how well the lungs exchange gases | 156 | $9,443 | $59 |
See all 13 services
| Long return visit (40+ min) | 176 | $52,889 | $164 |
| Return visit (30+ min) | 170 | $30,480 | $111 |
| Critical care, first 30-74 minutes | 40 | $18,074 | $186 |
| New patient visit (60+ min) | 55 | $10,997 | $200 |
| Test to examine how well the lungs exchange gases | 156 | $9,443 | $59 |
| Test to determine lung volumes using sensors | 154 | $9,224 | $59 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 232 | $5,593 | $15 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 144 | $5,561 | $38 |
| New patient visit (45+ min) | 38 | $5,338 | $140 |
| Critical care, each additional 30 minutes | 22 | $4,313 | $94 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 17 | $4,161 | $107 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 14 | $477 | $30 |
| Test to measure expiratory airflow and volume | 13 | $375 | $29 |
Who their Medicare patients are
361 Original Medicare patients in 2024. Average age 79 · Women 55% · Also on Medicaid 11% · Health risk score 1.78. At or below the middle of the specialty; the typical critical care (intensivists) clinician is at 2.58.
Conditions among them: High blood pressure 75% · COPD 46% · Coronary heart disease 44% · Diabetes 34% · Atrial fibrillation 33% · Heart failure 32% · Chronic kidney disease 31% · Cancer 26% · Depression 22% · Stroke 12% · Dementia 10%.
The office billed $771,342, Medicare allowed $279,032 and paid $214,091; for 3,333 services of 29 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 361 | 3,333 | 79 | 1.78 | $771,342 | $214,091 |
| 2023 | 375 | 2,000 | 78 | 1.93 | $576,875 | $153,218 |
| 2022 | 537 | 2,083 | 78 | 2.02 | $1,038,825 | $249,361 |
| 2021 | 452 | 1,646 | 78 | 2.04 | $834,357 | $214,599 |
| 2020 | 476 | 1,807 | 78 | 2.10 | $885,203 | $234,243 |
| 2019 | 631 | 2,771 | 79 | 2.35 | $1,360,209 | $329,918 |
| 2018 | 529 | 1,914 | 78 | 2.18 | $942,379 | $233,913 |
| 2017 | 510 | 1,680 | 78 | 2.33 | $724,628 | $215,825 |
| 2016 | 508 | 1,950 | 77 | 2.56 | $638,621 | $257,627 |
| 2015 | 553 | 2,175 | 76 | 2.41 | $677,866 | $285,434 |
| 2014 | 477 | 2,130 | 77 | 2.09 | $631,090 | $262,037 |
| 2013 | 160 | 682 | 76 | 2.04 | $202,945 | $81,956 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 9 services
| Return visit (30+ min) | 227 | $52,130 | $114 |
| Long return visit (40+ min) | 79 | $20,772 | $172 |
| Critical care, first 30-74 minutes | 44 | $19,150 | $195 |
| New patient visit (45+ min) | 79 | $11,838 | $150 |
| Test to examine how well the lungs exchange gases | 148 | $9,069 | $59 |
| Test to determine lung volumes using sensors | 148 | $8,680 | $57 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 31 | $8,098 | $111 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 144 | $5,713 | $38 |
| New patient visit (60+ min) | 21 | $4,177 | $199 |
2022: 14 services
| Critical care, first 30-74 minutes | 165 | $93,086 | $195 |
| Return visit (30+ min) | 219 | $55,101 | $117 |
| Long return visit (40+ min) | 80 | $20,072 | $167 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 99 | $19,883 | $95 |
| New patient visit (45+ min) | 74 | $11,201 | $151 |
| Test to examine how well the lungs exchange gases | 156 | $9,972 | $60 |
| Test to determine lung volumes using sensors | 157 | $9,344 | $56 |
| Critical care, each additional 30 minutes | 48 | $8,049 | $98 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 144 | $5,913 | $39 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 27 | $5,289 | $189 |
| New patient visit (60+ min) | 18 | $3,354 | $186 |
| Emergent insertion of breathing tube into windpipe using an endoscope | 11 | $1,361 | $124 |
| Test to measure expiratory airflow and volume | 16 | $456 | $28 |
| Ultrasonic guidance for blood vessel access | 11 | $136 | $12 |
2021: 13 services
| Critical care, first 30-74 minutes | 181 | $96,825 | $203 |
| Return visit (30+ min) | 167 | $39,456 | $120 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 97 | $19,249 | $97 |
| New patient visit (45+ min) | 67 | $10,121 | $151 |
| Long return visit (40+ min) | 46 | $9,668 | $176 |
| Critical care, each additional 30 minutes | 38 | $6,261 | $101 |
| Test to examine how well the lungs exchange gases | 85 | $5,499 | $62 |
| Telephone medical discussion with physician, 21-30 minutes | 39 | $5,069 | $92 |
| Test to determine lung volumes using sensors | 85 | $5,057 | $57 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 23 | $4,490 | $187 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 82 | $3,892 | $47 |
| New patient visit (60+ min) | 15 | $2,885 | $192 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 19 | $1,635 | $65 |
2020: 16 services
| Critical care, first 30-74 minutes | 209 | $124,624 | $206 |
| Return visit (30+ min) | 125 | $21,007 | $99 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 103 | $17,165 | $98 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 81 | $11,219 | $67 |
| Telephone medical discussion with physician, 21-30 minutes | 71 | $11,200 | $113 |
| New patient visit (45+ min) | 57 | $8,946 | $157 |
| Long return visit (40+ min) | 38 | $7,053 | $141 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 34 | $6,640 | $190 |
| Critical care, each additional 30 minutes | 39 | $5,546 | $103 |
| Test to examine how well the lungs exchange gases | 61 | $3,926 | $63 |
| Test to determine lung volumes using sensors | 61 | $3,685 | $59 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 54 | $3,530 | $65 |
| Emergent insertion of breathing tube into windpipe using an endoscope | 21 | $2,783 | $126 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 11 | $851 | $77 |
| Ultrasonic guidance for blood vessel access | 11 | $146 | $13 |
| Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 19 | $2 | None |
2019: 19 services
| Critical care, first 30-74 minutes | 346 | $195,315 | $199 |
| Return visit (30+ min) | 162 | $36,884 | $97 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 140 | $20,613 | $66 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 120 | $15,817 | $95 |
| New patient visit (45+ min) | 67 | $10,289 | $154 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 43 | $7,924 | $184 |
| Critical care, each additional 30 minutes | 51 | $6,877 | $100 |
| Long return visit (40+ min) | 44 | $5,979 | $133 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 92 | $5,588 | $61 |
| Test to examine how well the lungs exchange gases | 91 | $5,289 | $58 |
| Test to determine lung volumes using sensors | 91 | $5,130 | $56 |
| Emergent insertion of breathing tube into windpipe using an endoscope | 16 | $2,004 | $125 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 16 | $1,937 | $114 |
| Hospital discharge day management, more than 30 minutes | 19 | $1,852 | $97 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 22 | $1,678 | $76 |
| Aspiration of fluid from chest cavity using imaging guidance | 13 | $1,538 | $103 |
| Short return visit (20+ min) | 16 | $1,079 | $67 |
| Ultrasonic guidance for blood vessel access | 20 | $262 | $13 |
| Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 92 | $9 | None |
2018: 17 services
| Critical care, first 30-74 minutes | 280 | $132,214 | $196 |
| Return visit (30+ min) | 128 | $29,239 | $98 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 108 | $14,093 | $93 |
| New patient visit (45+ min) | 73 | $10,654 | $146 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 49 | $9,460 | $182 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 61 | $8,443 | $64 |
| Long return visit (40+ min) | 30 | $4,640 | $133 |
| Critical care, each additional 30 minutes | 38 | $4,316 | $98 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 57 | $3,357 | $59 |
| Test to determine lung volumes using sensors | 57 | $3,138 | $55 |
| Test to examine how well the lungs exchange gases | 56 | $2,984 | $53 |
| Emergent insertion of breathing tube into windpipe using an endoscope | 15 | $1,840 | $123 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 19 | $1,690 | $89 |
| Hospital discharge day management, more than 30 minutes | 11 | $1,185 | $99 |
| Short return visit (20+ min) | 22 | $1,110 | $46 |
| Ultrasonic guidance for blood vessel access | 11 | $141 | $13 |
| Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 52 | $6 | None |
2017: 17 services
| Critical care, first 30-74 minutes | 297 | $128,002 | $191 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 116 | $20,117 | $92 |
| Return visit (30+ min) | 98 | $19,704 | $98 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 77 | $10,119 | $62 |
| Short return visit (20+ min) | 71 | $6,298 | $68 |
| New patient visit (45+ min) | 40 | $5,776 | $144 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $4,389 | $176 |
| Critical care, each additional 30 minutes | 19 | $2,460 | $98 |
| Hospital discharge day management, more than 30 minutes | 24 | $2,357 | $98 |
| Emergent insertion of breathing tube into windpipe using an endoscope | 18 | $2,332 | $123 |
| Long return visit (40+ min) | 17 | $2,301 | $128 |
| New patient visit (60+ min) | 11 | $1,949 | $177 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 18 | $1,906 | $106 |
| New patient visit (30+ min) | 15 | $1,450 | $97 |
| Insertion of artery tube for blood sampling or infusion through skin | 14 | $669 | $45 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 17 | $526 | $31 |
| Test to examine how well the lungs exchange gases | 17 | $471 | $28 |
2016: 18 services
| Critical care, first 30-74 minutes | 322 | $170,995 | $191 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 129 | $24,529 | $89 |
| Return visit (30+ min) | 83 | $13,765 | $92 |
| Long return visit (40+ min) | 57 | $13,183 | $129 |
| New patient visit (60+ min) | 50 | $8,920 | $178 |
| Critical care, each additional 30 minutes | 46 | $5,387 | $96 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 35 | $4,663 | $62 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 17 | $2,551 | $150 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 19 | $2,290 | $104 |
| Emergent insertion of breathing tube into windpipe using an endoscope | 16 | $1,773 | $93 |
| Hospital discharge day management, more than 30 minutes | 19 | $1,715 | $90 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 45 | $530 | $11 |
| Test to determine lung volumes using gas dilution or washout | 46 | $509 | $10 |
| Test to examine how well the lungs exchange gases | 46 | $377 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 17 | $196 | $12 |
| Test to determine lung volumes using gas dilution or washout | 17 | $185 | $11 |
| Test to examine how well the lungs exchange gases | 16 | $128 | $8 |
| Test to measure expiratory airflow and volume | 14 | $104 | $7 |
2015: 18 services
| Critical care, first 30-74 minutes | 344 | $172,318 | $193 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 234 | $54,076 | $91 |
| New patient visit (60+ min) | 77 | $14,137 | $184 |
| Return visit (30+ min) | 79 | $13,324 | $98 |
| Long return visit (40+ min) | 35 | $6,252 | $133 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 30 | $5,525 | $178 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 38 | $4,519 | $64 |
| Hospital discharge day management, more than 30 minutes | 43 | $4,126 | $96 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 23 | $2,936 | $105 |
| New patient visit (45+ min) | 11 | $1,370 | $125 |
| Emergent insertion of breathing tube into windpipe using an endoscope | 13 | $1,222 | $94 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 41 | $490 | $12 |
| Test to determine lung volumes using gas dilution or washout | 41 | $462 | $11 |
| Pulmonary exercise testing | 12 | $350 | $27 |
| Test to examine how well the lungs exchange gases | 41 | $341 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 16 | $186 | $12 |
| Test to determine lung volumes using gas dilution or washout | 16 | $175 | $11 |
| Test to examine how well the lungs exchange gases | 16 | $129 | $8 |
2014: 18 services
| Critical care, first 30-74 minutes | 270 | $143,961 | $195 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 230 | $56,653 | $92 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 113 | $17,101 | $64 |
| New patient visit (45+ min) | 50 | $7,359 | $147 |
| Hospital discharge day management, more than 30 minutes | 64 | $6,275 | $97 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 30 | $5,756 | $180 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 39 | $4,482 | $107 |
| Return visit (30+ min) | 28 | $4,103 | $100 |
| Short return visit (20+ min) | 34 | $3,459 | $65 |
| Emergent insertion of breathing tube into windpipe using an endoscope | 19 | $1,815 | $96 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 11 | $1,077 | $90 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 22 | $258 | $12 |
| Test to determine lung volumes using gas dilution or washout | 22 | $243 | $11 |
| Test to examine how well the lungs exchange gases | 22 | $180 | $8 |
| Test to determine lung volumes using gas dilution or washout | 11 | $133 | $11 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 11 | $129 | $11 |
| Test to measure expiratory airflow and volume | 14 | $106 | $8 |
| Test to examine how well the lungs exchange gases | 12 | $100 | $8 |
2013: 5 services
| Critical care, first 30-74 minutes | 89 | $46,130 | $188 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 60 | $14,218 | $89 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 55 | $8,876 | $62 |
| Hospital discharge day management, more than 30 minutes | 31 | $3,016 | $94 |
| New patient visit (45+ min) | 16 | $2,296 | $144 |
Drugs they prescribed that Part D paid
$481,142
Pharmacies billed $481,142 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 851) in 2024. At or below the middle of the specialty; the typical critical care (intensivists) clinician is at 0%.
242 generic and 609 brand-name prescriptions · $481,142 in drug cost · 38 antibiotic prescriptions to 23 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Trelegy Ellipta | 144 | $116,063 | $806 |
| Ambrisentan | 16 | $62,173 | $3,886 |
| Anoro Ellipta | 97 | $51,817 | $534 |
| Breztri Aerosphere | 47 | $41,039 | $873 |
| Stiolto Respimat | 59 | $25,647 | $435 |
See all 21 drugs
| Trelegy Ellipta | 144 | $116,063 | $806 |
| Ambrisentan | 16 | $62,173 | $3,886 |
| Anoro Ellipta | 97 | $51,817 | $534 |
| Breztri Aerosphere | 47 | $41,039 | $873 |
| Stiolto Respimat | 59 | $25,647 | $435 |
| Spiriva Respimat | 25 | $21,511 | $860 |
| Breo Ellipta | 26 | $20,245 | $779 |
| Symbicort | 38 | $12,255 | $323 |
| Incruse Ellipta | 18 | $8,101 | $450 |
| Advair Hfa | 18 | $6,482 | $360 |
| Breyna | 23 | $4,796 | $209 |
| Budesonide-Formoterol | 19 | $4,747 | $250 |
| Mycophenolate Mofetil | 17 | $3,496 | $206 |
| Albuterol Sulfate Hfa | 100 | $2,323 | $23 |
| Wixela Inhub | 15 | $1,391 | $93 |
| Ventolin Hfa | 13 | $705 | $54 |
| Fluticasone Propionate | 15 | $334 | $22 |
| Prednisone | 15 | $149 | $10 |
| Amoxicillin-Clavulanate Potass | 12 | $76 | $6 |
| Methylprednisolone | 15 | $69 | $5 |
| Azithromycin | 16 | $38 | $2 |
Year by year
| 2024 | 851 | 177 | 0% (0) | 72% | $481,142 |
| 2023 | 846 | 170 | None | 74% | $466,402 |
| 2022 | 760 | 155 | None | 70% | $529,688 |
| 2021 | 681 | 134 | None | 75% | $361,289 |
| 2020 | 636 | 131 | 0% (0) | 69% | $206,918 |
| 2019 | 457 | 112 | 0% (0) | 73% | $144,343 |
| 2018 | 367 | 80 | 0% (0) | 69% | $114,929 |
| 2017 | 298 | 76 | 0% (0) | 71% | $126,741 |
| 2016 | 260 | 65 | None | 69% | $64,620 |
| 2015 | 226 | 51 | 0% (0) | 70% | $43,827 |
| 2014 | 164 | 36 | None | 46% | $24,032 |
| 2013 | 162 | 29 | 0% (0) | 45% | $20,903 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 16 drugs
| Trelegy Ellipta | 132 | $115,627 | $876 |
| Breztri Aerosphere | 68 | $53,695 | $790 |
| Anoro Ellipta | 70 | $40,385 | $577 |
| Stiolto Respimat | 69 | $36,034 | $522 |
| Spiriva Respimat | 49 | $33,865 | $691 |
| Symbicort | 72 | $30,771 | $427 |
| Breo Ellipta | 29 | $19,393 | $669 |
| Advair Diskus | 18 | $7,610 | $423 |
| Albuterol Sulfate Hfa | 86 | $2,745 | $32 |
| Mycophenolate Mofetil | 21 | $2,301 | $110 |
| Ventolin Hfa | 17 | $1,046 | $62 |
| Montelukast | 18 | $510 | $28 |
| Fluticasone Propionate | 21 | $311 | $15 |
| Prednisone | 27 | $172 | $6 |
| Azithromycin | 17 | $143 | $8 |
| Amoxicillin-Clavulanate Potass | 13 | $112 | $9 |
2022: 17 drugs
| Adempas | 11 | $134,506 | $12,228 |
| Trelegy Ellipta | 107 | $86,696 | $810 |
| Stiolto Respimat | 75 | $41,413 | $552 |
| Anoro Ellipta | 73 | $37,821 | $518 |
| Spiriva Respimat | 50 | $34,403 | $688 |
| Symbicort | 52 | $21,388 | $411 |
| Breztri Aerosphere | 24 | $20,748 | $864 |
| Breo Ellipta | 23 | $13,526 | $588 |
| Incruse Ellipta | 19 | $12,878 | $678 |
| Advair Diskus | 12 | $7,195 | $600 |
| Albuterol Sulfate Hfa | 53 | $2,543 | $48 |
| Mycophenolate Mofetil | 20 | $1,999 | $100 |
| Colchicine | 12 | $1,411 | $118 |
| Azithromycin | 17 | $475 | $28 |
| Montelukast | 26 | $473 | $18 |
| Prednisone | 18 | $225 | $12 |
| Methylprednisolone | 19 | $185 | $10 |
2021: 17 drugs
| Spiriva Respimat | 66 | $44,328 | $672 |
| Trelegy Ellipta | 67 | $42,626 | $636 |
| Stiolto Respimat | 70 | $38,383 | $548 |
| Anoro Ellipta | 63 | $30,867 | $490 |
| Breo Ellipta | 37 | $15,188 | $410 |
| Incruse Ellipta | 28 | $13,489 | $482 |
| Advair Diskus | 19 | $12,268 | $646 |
| Symbicort | 23 | $10,101 | $439 |
| Eliquis | 12 | $6,334 | $528 |
| Daliresp | 11 | $4,645 | $422 |
| Fluticasone-Salmeterol | 18 | $2,450 | $136 |
| Albuterol Sulfate Hfa | 61 | $2,402 | $39 |
| Arnuity Ellipta | 12 | $2,222 | $185 |
| Azithromycin | 29 | $1,099 | $38 |
| Prednisone | 17 | $226 | $13 |
| Methylprednisolone | 12 | $71 | $6 |
| Furosemide | 11 | $28 | $3 |
2020: 17 drugs
| Spiriva Respimat | 68 | $43,111 | $634 |
| Stiolto Respimat | 82 | $39,385 | $480 |
| Symbicort | 37 | $22,218 | $600 |
| Incruse Ellipta | 38 | $19,277 | $507 |
| Trelegy Ellipta | 29 | $17,450 | $602 |
| Anoro Ellipta | 26 | $11,382 | $438 |
| Breo Ellipta | 26 | $10,915 | $420 |
| Mycophenolate Mofetil | 14 | $3,537 | $253 |
| Arnuity Ellipta | 14 | $3,373 | $241 |
| Fluticasone-Salmeterol | 12 | $1,586 | $132 |
| Albuterol Sulfate Hfa | 27 | $1,184 | $44 |
| Proair Hfa | 12 | $832 | $69 |
| Ethambutol | 12 | $651 | $54 |
| Fluticasone Propionate | 17 | $547 | $32 |
| Azithromycin | 20 | $326 | $16 |
| Prednisone | 22 | $234 | $11 |
| Methylprednisolone | 18 | $112 | $6 |
2019: 12 drugs
| Spiriva Respimat | 105 | $55,209 | $526 |
| Symbicort | 39 | $18,368 | $471 |
| Stiolto Respimat | 28 | $13,447 | $480 |
| Incruse Ellipta | 13 | $11,434 | $880 |
| Anoro Ellipta | 11 | $4,777 | $434 |
| Fluticasone-Salmeterol | 13 | $2,379 | $183 |
| Ventolin Hfa | 25 | $1,423 | $57 |
| Proair Hfa | 15 | $1,011 | $67 |
| Albuterol Sulfate Hfa | 14 | $639 | $46 |
| Fluticasone Propionate | 13 | $243 | $19 |
| Amoxicillin-Clavulanate Potass | 11 | $162 | $15 |
| Prednisone | 19 | $114 | $6 |
2018: 10 drugs
| Spiriva Respimat | 55 | $26,843 | $488 |
| Advair Diskus | 50 | $23,755 | $475 |
| Symbicort | 24 | $8,360 | $348 |
| Incruse Ellipta | 19 | $7,864 | $414 |
| Spiriva | 12 | $7,274 | $606 |
| Flovent Hfa | 14 | $3,997 | $286 |
| Proair Hfa | 19 | $1,196 | $63 |
| Prednisone | 36 | $234 | $7 |
| Fluticasone Propionate | 15 | $166 | $11 |
| Amlodipine Besylate | 13 | $111 | $9 |
2017: 10 drugs
| Adcirca | 14 | $44,377 | $3,170 |
| Spiriva Respimat | 44 | $21,723 | $494 |
| Advair Diskus | 38 | $20,798 | $547 |
| Symbicort | 29 | $10,611 | $366 |
| Spiriva | 12 | $6,379 | $532 |
| Incruse Ellipta | 14 | $4,478 | $320 |
| Proair Hfa | 14 | $796 | $57 |
| Fluticasone Propionate | 12 | $139 | $12 |
| Amoxicillin-Clavulanate Potass | 13 | $136 | $10 |
| Prednisone | 13 | $77 | $6 |
2016: 6 drugs
| Advair Diskus | 47 | $22,921 | $488 |
| Symbicort | 31 | $9,801 | $316 |
| Spiriva | 14 | $6,572 | $469 |
| Tudorza Pressair | 12 | $3,627 | $302 |
| Proair Hfa | 18 | $1,171 | $65 |
| Amoxicillin-Clavulanate Potass | 12 | $250 | $21 |
2015: 7 drugs
| Advair Diskus | 55 | $19,598 | $356 |
| Spiriva | 14 | $7,313 | $522 |
| Tudorza Pressair | 12 | $3,371 | $281 |
| Proair Hfa | 21 | $1,284 | $61 |
| Azithromycin | 16 | $232 | $15 |
| Prednisone | 12 | $221 | $18 |
| Montelukast | 16 | $128 | $8 |
2014: 3 drugs
| Spiriva | 31 | $9,426 | $304 |
| Advair Diskus | 19 | $5,420 | $285 |
| Enoxaparin | 11 | $2,740 | $249 |
2013: 3 drugs
| Spiriva | 24 | $7,618 | $317 |
| Azithromycin | 22 | $770 | $35 |
| Omeprazole | 12 | $169 | $14 |
Money from drug and device companies
$783 in 2025
| 2025 | 9 | 33 | None | $783 |
| 2024 | 4 | 20 | None | $456 |
| 2023 | 4 | 21 | None | $413 |
| 2022 | 3 | 15 | None | $190 |
| 2021 | 1 | 2 | None | $37 |
| 2020 | 2 | 21 | None | $334 |
| 2019 | 5 | 26 | None | $578 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| GlaxoSmithKline | Nucala | $223 | 11 payments
|
| AstraZeneca Pharmaceuticals LP | Tezspire | $220 | 8 payments
|
| Genzyme | Dupixent | $117 | 5 payments
|
| Sanofi-Aventis U.S. | Dupixent | $60 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Ofev | $48 | 2 payments
|
| Verona Pharma | Ohtuvayre | $34 | 1 payment
|
See all 32 published payments
| GlaxoSmithKline | Meals · 2025-12-18 | Nucala | $14 |
| Insmed | Meals · 2025-11-07 | Arikayce | $14 |
| GlaxoSmithKline | Meals · 2025-11-06 | Nucala | $23 |
| Insmed | Meals · 2025-10-03 | Arikayce | $16 |
| Sanofi-Aventis U.S. | Education · 2025-08-15 | Dupixent | $60 |
| Genzyme | Meals · 2025-07-17 | Dupixent | $27 |
| GlaxoSmithKline | Meals · 2025-06-24 | Nucala | $17 |
| Genzyme | Meals · 2025-06-12 | Dupixent | $15 |
| GlaxoSmithKline | Meals · 2025-06-03 | Nucala | $14 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-05-28 | Fasenra | $25 |
| Genzyme | Meals · 2025-05-21 | Dupixent | $24 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-05-14 | Tezspire | $26 |
| GlaxoSmithKline | Meals · 2025-05-12 | Nucala | $20 |
| Viatris Specialty | Meals · 2025-05-06 | Yupelri | $21 |
| GlaxoSmithKline | Meals · 2025-04-30 | Trelegy Ellipta | $31 |
| Philips North America | Meals · 2025-04-23 | Vest Therapy Und | $30 |
| GlaxoSmithKline | Meals · 2025-04-16 | Nucala | $23 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-04-09 | Tezspire | $34 |
| Genzyme | Meals · 2025-04-04 | Dupixent | $25 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-27 | Airsupra | $30 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-27 | Fasenra | $24 |
| GlaxoSmithKline | Meals · 2025-03-19 | Trelegy Ellipta | $34 |
| GlaxoSmithKline | Meals · 2025-03-17 | Nucala | $20 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-03-11 | Ofev | $25 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-10 | Airsupra | $20 |
| Genzyme | Meals · 2025-03-05 | Dupixent | $27 |
| GlaxoSmithKline | Meals · 2025-02-25 | Nucala | $3 |
| GlaxoSmithKline | Meals · 2025-02-25 | Nucala | $24 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-22 | Tezspire | $30 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-02-06 | Ofev | $24 |
| Verona Pharma | Meals · 2025-02-06 | Ohtuvayre | $34 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-01-31 | Airsupra | $31 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $456
| AstraZeneca Pharmaceuticals LP | Airsupra | $301 | 10 payments
|
| Genzyme | Dupixent | $92 | 4 payments
|
| Amgen | Tezspire | $33 | 1 payment
|
| Philips North America | (8874) Incourage | $30 | 1 payment
|
2023: $413
| AstraZeneca Pharmaceuticals LP | Fasenra | $309 | 6 payments
|
| Philips Electronics North America | (8874) Incourage | $64 | 3 payments
|
| GlaxoSmithKline | Trelegy Ellipta | $26 | 1 payment
|
| Genzyme | Dupixent | $14 | 1 payment
|
2022: $190
| AstraZeneca Pharmaceuticals LP | Tezspire | $119 | 4 payments
|
| GlaxoSmithKline | Nucala | $48 | 2 payments
|
| Genentech USA | Xolair | $24 | 1 payment
|
2021: $37
| GlaxoSmithKline | Nucala | $37 | 2 payments
|
2020: $334
| GlaxoSmithKline | Anoro Ellipta | $259 | 18 payments
|
| Insmed | Arikayce | $75 | 3 payments
|
2019: $578
| GlaxoSmithKline | Nucala | $206 | 17 payments
|
| Insmed | Arikayce | $204 | 6 payments
|
| Abbott Laboratories | Heartmate 3 Left Ventricular Dev | $131 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Spiriva Respimat | $21 | 1 payment
|
| Genentech USA | Esbriet | $17 | 1 payment
|
Professional record
- NPI
- 1013176213
- Licence
- CA A105896California A105896: Current · expires 2028-04-30
- Trained
- Geisel School of Medicine at Dartmouth, 2007
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207RC0200X (207RC0200X); Internal medicine (207R00000X); Federal specialty code 207RP1001X (207RP1001X)
- Mailing address
- Po Box 1869, Los Gatos, CA, 95031
- NPI first listed
- 2008-06-03
- NPI last updated
- 2016-08-18
This is when the NPI record was last certified, not a medical board exam.